Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
PaperCitations, authors & open-access status
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 331 citations, 2022 year and closed oa status.
331
Citations
2022
Year
closed
OA Status